An associated risk between lupus and cervical cancer has recently been confirmed in a study titled “Cervical dysplasia and cervical cancer in women with rheumatoid arthritis,” presented at the EULAR Congress 2016 June 8-11 in London. Known as systemic lupus erythematosus or SLE, lupus is a condition characterized by chronic autoimmune…
ImmuPharma, a specialized drug discovery and development pharmaceutical company, announced its Phase 3 clinical trial of Lupuzor (rigerimod), the company’s lead potential breakthrough lupus treatment candidate, has made progress and has begun dosing its first European patients. In its update, ImmunoPharma said the Lupuzor Phase 3 study will enroll…
Researchers at Sun Yat-sen University in China have found that a group of anti-nuclear antibodies that target double stranded DNA, anti-dsDNA, may cause inflammation in systemic lupus erythomatosus (SLE) patients, through the activation of a particular molecular inflammasome. The findings were revealed in the study “Anti-dsDNA antibodies bind to TLR4…
Four key Lupus advocacy groups will host a Lupus Patient-Focused Drug Development Meeting next spring called “Lupus: Patient Voices,” according to a news release. The groups, the Alliance for Lupus Research (ALR), the Lupus Research Institute (LRI), the Lupus and Allied Diseases Association (LADA), and the Lupus Foundation of America (LFA), will lead the…
A patient-centered lupus drug development meeting, “Lupus: Patient Voices”, will be held in spring 2017. The Alliance for Lupus Research (ALR), the Lupus and Allied Diseases Association (LADA), Lupus Foundation of America (LFA), and the Lupus Research Institute (LRI) will organize the event that will focus on patient viewpoints, daily impacts…
Interferon gamma could be a key trigger for lupus, a finding that may provide information leading to new treatments for the autoimmune disease, according to researchers at Penn State College of Medicine. The study, “IFN-γ receptor and STAT1 signaling in B cells are central to spontaneous germinal…
Resolve Therapeutics, a biopharma developing innovative therapies for Systemic Lupus Erythematosus (SLE) and Sjogrens syndrome, will present new data from two clinical studies at the EULAR Annual European Congress of Rheumatology, June 8-11, in London. The company’s scientific founder Dr. Keith Elkon will deliver the oral presentation “Immune Complex Bound…
Sanford Burnham Prebys Medical Discovery Research Institute researchers have uncovered a new protein called P-selectin glycoprotein ligand-1 (PSGL-1) that is involved in the regulation of T-cell immune responses, with implications in autoimmune diseases. The findings have recently been published in Immunity in a study titled “…
Various ethnic groups differ in what specific symptoms of systemic lupus erythematosus (SLE) they display — a difference that might be linked to the presence of different immune factors, according to a new study. Understanding how ethnicity might influence these differences can pave the way for treatments that are better…
Treatment of systemic lupus erythematosus (SLE) needs to reflect the involvement of particular organs as well as the severity of disease, according to a study presented at the Congress of Clinical Rheumatology Annual Meeting, scrutinizing published clinical trials of lupus. The study advocated giving more weight to clinical experience…